Login / Signup

Evaluation of the Impact of Comorbidities on Omadacycline Pharmacokinetics.

Michael TrangE A LakotaM C SafirSujata M BhavnaniL FriedrichJ N SteenbergenP C McGovernE TzanisChristopher M Rubino
Published in: Antimicrobial agents and chemotherapy (2023)
Omadacycline is approved in the United States for the treatment of patients with community-acquired bacterial pneumonia or acute bacterial skin and skin structure infections. Analyses were undertaken to evaluate pharmacokinetic differences among subjects or patients stratified by comorbidities. Differences in clearance by smoking status, history of diabetes mellitus, chronic lung disease, hypertension, heart failure, or coronary artery disease were evaluated using a Welch two-sample t test. Smoking was the only significant comorbidity after correction for sex, with a clinically insignificant difference of 13%. Omadacycline dose adjustments based on these comorbidities do not appear to be warranted.
Keyphrases